Telix Pharmaceuticals Limited (NASDAQ: TLX) reported Q2 Revenue for the quarter came in at $247 million.

Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income received from Regeneron

For earnings history and earnings-related data on Telix Pharmaceuticals Limited (TLX) click here.